KRAS is a proto-oncogene that is mutated in a wide variety of human cancers. Although this makes KRAS an obvious candidate for the development of targeted therapies, it has so far remained refractory to this approach. Systematic RNA interference is now used to detect synthetic lethal partners of oncogenic KRAS, revealing that TBK1 and NF-κB signalling are essential in KRAS mutant tumours. This may provide an alternative approach for targeting KRAS therapeutically.
- David A. Barbie
- Pablo Tamayo
- William C. Hahn
